Astrabio Joins Forces with Eisai and BKGI in Thailand to Advance Alzheimer’s Care
Bangkok, Thailand – Astrabio, a global innovator in neurobiomarker detection, was honored to participate as a special guest at the signing ceremony of the Memorandum of Understanding (MOU) between Eisai (Thailand) Marketing Co., Ltd. (Eisai) and Bangkok Genomics Innovation PLC. (BKGI). This groundbreaking collaboration aims to enhance Alzheimer’s disease (AD) screening and treatment, laying the foundation for a comprehensive care ecosystem in Thailand.
Astrabio’s CEO, Mr. Benny Yan, was invited to deliver a keynote address on "Blood Biomarker Technology Best Practice Sharing," where he highlighted the transformative potential of advanced biomarker detection in early Alzheimer’s screening and precision medicine.
Astrabio’s contribution to the event underscored the importance of cutting-edge biomarker technologies in this effort. The company’s single-molecule immunodetection platform provides highly sensitive and accurate measurements of Alzheimer’s-related biomarkers such as amyloid beta and phosphorylated tau (p-tau).
“We are delighted to witness this pivotal collaboration between Eisai and BKGI, two leaders in their respective fields,” said Mr. Benny Yan. “Astrabio is committed to supporting initiatives that bring early screening and early intervention to the forefront of Alzheimer’s care. It’s inspiring to see such synergy driving progress in precision medicine.”
As Dr. Thosaporn Sirisumphand, Chairman of the Board at BKGI, remarked during the event, “Early screening for Alzheimer’s disease is the key to effective treatment. This collaboration represents a significant step in expanding Thailand’s precision medicine landscape.”
